JPWO2020208177A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020208177A5 JPWO2020208177A5 JP2021559827A JP2021559827A JPWO2020208177A5 JP WO2020208177 A5 JPWO2020208177 A5 JP WO2020208177A5 JP 2021559827 A JP2021559827 A JP 2021559827A JP 2021559827 A JP2021559827 A JP 2021559827A JP WO2020208177 A5 JPWO2020208177 A5 JP WO2020208177A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- seq
- variant
- fcrn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 128
- 230000027455 binding Effects 0.000 claims description 64
- 239000012634 fragment Substances 0.000 claims description 51
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 49
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 49
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 206010034277 Pemphigoid Diseases 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 9
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 8
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 8
- 208000024376 chronic urticaria Diseases 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 208000037908 antibody-mediated disorder Diseases 0.000 claims description 6
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 206010036105 Polyneuropathy Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 4
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 4
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims description 4
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 206010043207 temporal arteritis Diseases 0.000 claims description 4
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000007824 polyneuropathy Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 2
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 201000002829 CREST Syndrome Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 108010073816 IgE Receptors Proteins 0.000 claims description 2
- 102000009438 IgE Receptors Human genes 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 206010033661 Pancytopenia Diseases 0.000 claims description 2
- 208000027086 Pemphigus foliaceus Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 230000002052 anaphylactic effect Effects 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000006424 autoimmune oophoritis Diseases 0.000 claims description 2
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000029407 autoimmune urticaria Diseases 0.000 claims description 2
- 210000003651 basophil Anatomy 0.000 claims description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 208000024389 cytopenia Diseases 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000005737 orchitis Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000019629 polyneuritis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 206010018852 Haematoma Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 description 19
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102000044708 Eosinophil peroxidases Human genes 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1905150.7 | 2019-04-11 | ||
| GB1905150.7A GB2589049C (en) | 2019-04-11 | 2019-04-11 | Anti-IgE antibodies |
| PCT/EP2020/060240 WO2020208177A1 (en) | 2019-04-11 | 2020-04-09 | ANTI-IgE ANTIBODIES |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022528927A JP2022528927A (ja) | 2022-06-16 |
| JP2022528927A5 JP2022528927A5 (https=) | 2023-04-18 |
| JPWO2020208177A5 true JPWO2020208177A5 (https=) | 2023-04-18 |
| JP7586833B2 JP7586833B2 (ja) | 2024-11-19 |
Family
ID=66809886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559827A Active JP7586833B2 (ja) | 2019-04-11 | 2020-04-09 | 抗ＩｇＥ抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20220177604A1 (https=) |
| EP (1) | EP3953396A1 (https=) |
| JP (1) | JP7586833B2 (https=) |
| KR (1) | KR20210150430A (https=) |
| CN (1) | CN113939540A (https=) |
| AU (1) | AU2020271405A1 (https=) |
| BR (1) | BR112021020329A2 (https=) |
| CA (1) | CA3133941A1 (https=) |
| EA (1) | EA202192785A1 (https=) |
| GB (1) | GB2589049C (https=) |
| IL (1) | IL287035A (https=) |
| MA (1) | MA55600A (https=) |
| MX (1) | MX2021012457A (https=) |
| PH (1) | PH12021552545A1 (https=) |
| SG (1) | SG11202110247XA (https=) |
| WO (1) | WO2020208177A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022013554A2 (pt) | 2020-01-08 | 2022-09-06 | argenx BV | Métodos para tratar distúrbios do pênfigo |
| AU2022310356A1 (en) | 2021-07-14 | 2024-01-25 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| EP4431528A1 (en) * | 2021-10-29 | 2024-09-18 | Longbio Pharma (Suzhou) Co., Ltd. | Isolated antigen binding protein and use thereof |
| CA3258000A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE |
| GB2635291A (en) | 2022-07-01 | 2025-05-07 | Alk Abello As | Displacers of IgE-FCERI |
| CN115724951B (zh) * | 2022-11-15 | 2023-10-03 | 怡道生物科技(苏州)有限公司 | 与11型hpv结合的抗体或其抗原结合片段及其应用 |
| JP2026503461A (ja) * | 2023-01-18 | 2026-01-29 | ライシア セラピューティクス， インコーポレイテッド | サイクリングリソソーム標的化抗体コンジュゲート |
| CN118725128B (zh) * | 2023-03-28 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 抗IgE抗体、检测IgE的试剂和试剂盒 |
| CN119490594B (zh) * | 2023-08-15 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 一种抗免疫球蛋白e的抗体及其应用 |
| EP4530295A3 (en) * | 2023-09-07 | 2025-05-28 | argenx BV | Fcrn antagonists and methods of use |
| GB202318512D0 (en) * | 2023-12-04 | 2024-01-17 | argenx BV | Methods of determining potency |
| WO2025229224A1 (en) * | 2024-05-03 | 2025-11-06 | argenx BV | Monovalent anti-iga binding molecules and methods of use |
| US12509529B2 (en) | 2024-05-17 | 2025-12-30 | Excellergy, Inc. | Antibodies and antibody fragments that bind IgE |
| WO2025255496A1 (en) * | 2024-06-07 | 2025-12-11 | Nuvig Therapeutics, Inc. | Modified fc polypeptides |
| WO2026015664A1 (en) * | 2024-07-10 | 2026-01-15 | Lycia Therapeutics, Inc. | Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige) |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2467781C (en) | 2000-11-20 | 2014-09-23 | Canadian Blood Services | Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| DE60334141D1 (de) | 2002-10-15 | 2010-10-21 | Facet Biotech Corp | VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| WO2004062619A2 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF |
| SI2000481T1 (sl) | 2003-02-01 | 2016-08-31 | Tanox, Inc. | Anti-humana protitelesa IgE z visoko afiniteto |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| CN112142843B (zh) * | 2013-12-24 | 2024-10-18 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| FI3137504T3 (fi) * | 2014-04-30 | 2023-08-07 | Hanall Biopharma Co Ltd | Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten |
| MY188761A (en) * | 2015-03-09 | 2021-12-29 | Argenx Bvba | Method of reducing serum levels of fc-containing agents using fcrn antagonists |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| GB201707484D0 (en) * | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
-
2019
- 2019-04-11 GB GB1905150.7A patent/GB2589049C/en active Active
-
2020
- 2020-04-09 CN CN202080038130.8A patent/CN113939540A/zh active Pending
- 2020-04-09 EP EP20718649.5A patent/EP3953396A1/en active Pending
- 2020-04-09 JP JP2021559827A patent/JP7586833B2/ja active Active
- 2020-04-09 KR KR1020217034261A patent/KR20210150430A/ko not_active Ceased
- 2020-04-09 SG SG11202110247XA patent/SG11202110247XA/en unknown
- 2020-04-09 CA CA3133941A patent/CA3133941A1/en active Pending
- 2020-04-09 MA MA055600A patent/MA55600A/fr unknown
- 2020-04-09 BR BR112021020329A patent/BR112021020329A2/pt unknown
- 2020-04-09 WO PCT/EP2020/060240 patent/WO2020208177A1/en not_active Ceased
- 2020-04-09 PH PH1/2021/552545A patent/PH12021552545A1/en unknown
- 2020-04-09 EA EA202192785A patent/EA202192785A1/ru unknown
- 2020-04-09 AU AU2020271405A patent/AU2020271405A1/en active Pending
- 2020-04-09 MX MX2021012457A patent/MX2021012457A/es unknown
- 2020-04-09 US US17/598,033 patent/US20220177604A1/en not_active Abandoned
-
2021
- 2021-10-06 IL IL287035A patent/IL287035A/en unknown
-
2025
- 2025-07-02 US US19/257,976 patent/US20250388699A1/en active Pending
- 2025-07-02 US US19/258,059 patent/US20250388700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020208177A5 (https=) | ||
| US20250388700A1 (en) | Variant fc regions | |
| AU2019305663B2 (en) | Heavy chain antibodies binding to cd19 | |
| JP2018528258A5 (https=) | ||
| GB2517953A (en) | Antibodies to complex targets | |
| CA2302752A1 (en) | Humanized antibodies to human gp39, compositions containing and therapeutic use thereof | |
| JP2018509413A5 (https=) | ||
| US20260048122A1 (en) | Anti-cd19 antibodies and car-t structures | |
| US20250346682A1 (en) | Anti-cd20 antibodies and car-t structures | |
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| JP2025522482A (ja) | インターロイキン１３に結合する抗体及び使用方法 | |
| TWI749367B (zh) | Cd200r促效劑抗體及其用途 | |
| IL298075A (en) | St2 antigen binding protein | |
| JP2023514224A (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| CA3199586A1 (en) | Antigen-binding molecules and uses thereof | |
| US20250188161A1 (en) | TGF-ß ANTIBODIES | |
| WO2026076213A2 (en) | Anti-hsa antibody fusions and methods of use thereof | |
| HK40058421A (en) | Anti-ige antibodies | |
| EA050049B1 (ru) | Антитела к cd19 и car-t-клеточные структуры | |
| EA049400B1 (ru) | Антитела к ige | |
| RU2025102187A (ru) | Мутанты бычьих антител | |
| EA049498B1 (ru) | Антитела к cd20 и car-t-клеточные структуры | |
| CN117120472A (zh) | 抗cd19抗体及car-t结构 | |
| NZ739859A (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |